CClinicalTrials.gg
Active, not recruitingNCT07535749Updated Sep 4, 2026

The Effect of Myopia-Control Contact Lenses in New Zealand Chinese Children

A Phase 3 interventional study of MiSight Contact Lenses (CooperVision) and Albiliti 1-Day (Johnson and Johnson, VisionCare) in Myopia Progression, sponsored by Aston University. Active, not recruiting at 1 site in New Zealand. Open to participants aged 7 Years to 11 Years. Per ClinicalTrials.gov, last updated 2026-09-04.

Sponsored by Aston University · Phase 3, Interventional, and Prevention

Phase
Phase 3
Study type
Interventional
Enrollment
66
Allocation
Randomized
Ages
7 Years to 11 Years
Sex
All
01

Study summary

The study will employ a randomized, controlled, investigator-masked paired-eye comparison design to evaluate the effects of two myopia-control contact lenses-MiSight 1 Day and Abiliti 1-Day-in New Zealand Chinese children.

The study duration will be 12 months, with assessments conducted at baseline, 2 weeks, 3 months, 6 months and 12 months.

The clinical research will be conducted at the Auckland Myopia Clinic (New Zealand) and will follow a standard clinical routine for children with early myopia, the only difference being the randomizing of the MiSight and Abiliti contact lenses between the two eyes of the participants.

Read the detailed description
  1. Study Design The study will employ a randomized, controlled, investigator-masked paired-eye comparison design to evaluate the effects of two myopia-control contact lenses-MiSight 1 Day and Abiliti 1-Day-in New Zealand Chinese children. The study duration will be 6 months, with assessments conducted at baseline, 2 weeks, 3 months, and 6 months. The clinical research will be conducted at the Auckland Myopia Clinic (New Zealand) and will follow a standard clinical routine for children with early myopia, the only difference being the randomizing of the MiSight and Abiliti contact lenses between the two eyes of the participants.
  2. Participants 2.1 Recruitment and Eligibility Criteria • Participants: 53-66 New Zealand Chinese children aged 7-11 years.

    • Inclusion criteria:

      o Spherical refractive error between -1.00D and -4.50D

      o Astigmatism of ≤1.00D

      o No history of orthokeratology or atropine use

      o No ocular diseases or surgical history

    • Recruitment will be through social media, patient referrals, and school outreach.

    2.2 Sample Size A similar study, of soft contact lenses with novel ring focus for controlling myopia progression, based their sample size on treatment efficacy of >0.08 mm (standard deviation [SD]: 0.10) in axial elongation from baseline and >0.20 D (SD: 0.32) in change of spherical equivalent cycloplegic autorefraction (SECAR) from baseline at 26 weeks. Controlling the 2-sided type I error rate at the 0.05 level, the researchers found that sample size of 40 subjects per group would yield >80% power for detecting treatment efficacy.

    To estimate the sample size for the present study, a priori power analysis was performed using the program G∗Power (version 3.1.9.7). For a 95% confidence interval (Z = 1.96) and a study power of 80%, and controlling the 2-sided type I error rate at the 0.05 level, the estimated sample size is 53 pairs of eyes (53 subjects), as each participant contributes both eyes to the study. Providing for a 20% dropout rate, the recruitment target becomes 66 participants.

  3. Interventions

    Each participant will wear:

    • MiSight 1 Day dual-focus lens in one eye (2.00D defocus)
    • Abiliti 1-Day lens in the contralateral eye (7.00D defocus)
  4. Data Collection Methods 4.1 Baseline and Follow-up Assessments

    • Cycloplegic refraction (CycloRx) and retinoscopy (Ret) will be conducted.
    • Axial length will be measured using MYAH optical biometry.
    • Ocular surface assessments:

    o Children Dry Eye Questionnaire (CDEQ) responses

    o Non-invasive Tear break-up time (NIBUT) using MYAH's dry eye function

    o Ocular Protection Index (OPI) calculation using MYAH

    • Corneal staining assessment via MYAH corneal staining and slit lamp fluorescein
    • Lissamine green conjunctiva staining (graded and recorded) 4.2 Timepoints for Data Collection

      • Baseline (0 months): Cycloplegic refraction, axial length, CDEQ, NIBUT, OPI, corneal staining.
      • 2 weeks: Axial length, ocular surface assessments, dry eye symptoms.
      • 3 months: Axial length, ocular surface assessments, dry eye symptoms.
      • 6 months: Final assessments of axial length, ocular surface health, and dry eye symptoms.
  5. Outcome Measures

1. Myopia-control efficacy: Comparison of axial length elongation between the two contact lenses.

2. Ocular surface health:

o CDEQ responses

  • NIBUT measurements
  • OPI calculation
  • Corneal staining severity Should one lens slow the development of myopia more than the other, the lenses will be reversed at the end of the study.

    6. Parent Perception Questionnaire

A structured questionnaire will be administered at baseline and at 6 months to assess parents' expectations and perceptions of the contact lenses as a myopia treatment. Topics covered include:

  • Baseline Questionnaire: Motivations, barriers, facilitators, and expectations for contact lens treatment.
  • Follow-up Questionnaire: Changes in attitudes, satisfaction with treatment compared to initial expectations, and future adherence.

    7. Ethical Considerations The study will comply with optometric ethical standards. Participants and parents will provide informed consent. Data confidentiality will be maintained, and the study will be subject to institutional ethics review.

    8. Study Personnel The study will be investigator-masked and conducted by two paediatric optometrists,who each have extensive experience in myopia management. Both have conducted over 800 paediatric myopia exams.

    9. Statistical Analysis Data will be analysed using SPSS software. Axial length changes will be compared between paired eyes using paired t-tests. Dry eye symptoms and corneal staining scores will be analysed using a repeated measures ANOVA.

02

Conditions studied

  • Myopia Progression

Keywords

  • myopia control
  • contact lenses
03

In context

Lead sponsor

Aston University is the lead sponsor of 27 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
7 Years to 11 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Spherical refractive error between -1.00D and -4.50D
  • Astigmatism of ≤1.00D
  • No history of orthokeratology or atropine use
  • No ocular diseases or surgical history

Exclusion criteria

Exclusion Criteria:

o No ocular diseases or surgical history

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
66 participants (estimated)

Study arms

  • Active comparator
    MiSight Contact Lens

    Commercially available myopia control contact lens

    Device: MiSight Contact Lenses (CooperVision)

  • Active comparator
    Abiliti 1-Day

    Commercially available myopia control contact lens

    Device: Albiliti 1-Day (Johnson and Johnson, VisionCare)

Interventions

  • DeviceMiSight Contact Lenses (CooperVision)

    Myopia Control Contact Lens

  • DeviceAlbiliti 1-Day (Johnson and Johnson, VisionCare)

    Myopia Control Contact Lens

06

What researchers measure

Primary outcomes

  1. Mean Spherical Equivalent Cycloplegic Refraction

    The dioptric refractive error as determined by retinoscopy following cycloplegic refraction

    Time frame: Baseline, 2 weeks, 3 months, 6 months, 12 months

  2. Axial length

    Ocular biometry measured with Myah biometer

    Time frame: Baseline, 2 weeks, 3 months, 6 months, 12 months

Secondary outcomes

  1. Children Dry Eye Questionnaire (CDEQ) response

    Total score derived from the Children Dry Eye Questionnaire (CDEQ)

    Time frame: Baseline, 2 weeks, 3 months, 6 months, 12 months

  2. Non-invasive Tear break-up time

    Non-invasive Tear break-up time (NIBUT) using MYAH's objective dry eye function - time after a blink (in seconds) for the first break in the tear film to be detected

    Time frame: Baseline, 2 weeks, 3 months, 6 months, 12 months

  3. Ocular Protection Index

    Non-invasive breakup time secondary outcome measure divided by the average blink interval (number of blinks observed in a 60s period)

    Time frame: Baseline, 2 weeks, 3 months, 6 months, 12 months

  4. Corneal punctate spots

    Number of punctate spots observed on the cornea following instillation of fluorescein and illumination with a blue light source

    Time frame: Baseline, 2 weeks, 3 months, 6 months, 12 months

  5. Conjunctival punctate spots

    Number of puntate spots observed over the bulbar conjunctiva following instillation of lissamine green dye

    Time frame: Baseline, 2 weeks, 3 months, 6 months, 12 months

07

Study locations

1 site
  • Auckland Myopia Clinic
    Auckland, 1052, New Zealand
08

References and documents

Individual participant data

Plan to share: No — Patients have not given permission for this

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07535749
Lead sponsor
Aston University
Responsible party
Sponsor
First posted
Apr 17, 2026
Start date
Mar 21, 2026
Primary completion
Apr 30, 2027 (estimated)
Completion
May 30, 2027 (estimated)
Last update
Sep 4, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion